Paper Details

  1. Home
  2. Paper Details

Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Author: , ArevaloBert, BelknapRobert, BorisovAndrey S, CaylàJoan A, ChenMichael P, FengPei-Jean, HollandDavid, MartinsonNeil A, MilletJoan-Pau, MiróJosé M, MoroRuth N, ScottNigel A, VillarinoMargarita E, WeinerMarc, WrightAlicia

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Self-administered once-weekly isoniazid and rifapentine for latent tuberculosis infection is a viable alternative to directly observed therapy, particularly in the United States. In a randomized clinical trial, self-administration without reminders was noninferior to directly observed therapy. Treatment completion rates were 87.2% with direct observation, 74.0% with self-administration, and 76.4% with self-administration and reminders. Self-administration without reminders was the only group that met noninferiority criteria.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Expanding latent tuberculosis treatment is important to decrease active disease globally. Once-weekly isoniazid and rifapentine for 12 doses is effective but limited by requiring direct observation. OBJECTIVE: To compare treatment completion and safety of once-weekly isoniazid and rifap...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29114781

データ提供：米国国立医学図書館（NLM）

Latent Tuberculosis Infection: A New Frontier in Self-Administered Treatment

The global struggle against tuberculosis (TB) involves a constant search for innovative ways to prevent and treat the disease. This study explores the potential of self-administered treatment for latent TB infection, a condition that poses a silent threat to public health. The researchers conducted a randomized controlled trial to assess the efficacy and safety of self-administered once-weekly isoniazid and rifapentine compared to directly observed therapy.

Empowering Patients: Self-Administered Treatment for Latent TB

The study found that self-administered once-weekly isoniazid and rifapentine was non-inferior to direct observation in completing treatment in the United States. This finding suggests that self-administered treatment could be a viable option for patients in similar settings where direct observation is challenging. The study also highlighted the importance of text message reminders to improve treatment completion rates.

Addressing Latent TB Infection: A Global Challenge

The study emphasizes the importance of developing effective and accessible treatment strategies for latent TB infection, a condition that can progress to active disease. The findings suggest that self-administered treatment could be a valuable tool for tackling the global burden of TB.

Dr. Camel's Conclusion

This study is like a beacon of hope in the desert of TB research. It shows that self-administered once-weekly isoniazid and rifapentine can be effective in treating latent TB infection, especially in the United States. This approach could be a game-changer in reducing the burden of TB, as it offers a more convenient and accessible option for patients.

Date :
  1. Date Completed 2017-12-11
  2. Date Revised 2021-07-17
Further Info :

Pubmed ID

29114781

DOI: Digital Object Identifier

NIHMS928922

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.